MEG-002
Thrombocytopenia (Platelet Transfusion)
Phase 1Active (First-in-Human trial initiated June 2022)
Key Facts
Indication
Thrombocytopenia (Platelet Transfusion)
Phase
Phase 1
Status
Active (First-in-Human trial initiated June 2022)
Company
About Megakaryon
Developing mass-produced, allogeneic iPSC-derived platelet transfusions to overcome donor dependency and supply shortages in hematology.
View full company profile